Milestone Pharmaceuticals prices $30M public offering; net proceeds ~$32.4M

Milestone Pharmaceuticals Inc.

Offering of 16,666,667 common shares at $1.50/share and 3,333,333 pre-funded warrants at $1.499/warrant.
Underwriters' option for 3,000,000 additional common shares exercised in full.
Net proceeds of ~$32.4M to fund etripamil development for PSVT and AFib-RVR, plus working capital.
Expected to close on or about March 4, 2024, subject to customary conditions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Milestone Pharmaceuticals Inc. entered into Underwriting Agreement with Piper Sandler & Co. as representative of the several underwriters (effective 2024-02-28).

Action: entry
Agreement: underwriting
Counterparty: Piper Sandler & Co. as representative of the several underwriters
Effective: 2024-02-28

Exact text from the filing

On February 28, 2024, Milestone Pharmaceuticals Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co. as representative of the several underwriters listed on Schedule A thereto (the “Underwriters”), related to an underwritten public offering (the “Offering”) of 16,666,667 of the Company’s common shares, without par value (the “Common Shares”), at a public offering price of $1.50 per share

View on SEC.gov

737 material agreements filed in the last 30 days. Browse all material agreements →

Milestone Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-030267

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.